Hypo-Fractionated Radiotherapy in Breast Cancer

NCT03669497 | Completed DMC

• 1 other identifier: EC/TMC/108/17
• Study Type: interventional
• Target: 33
• Locations: 1 country
• Sites: 1

Brief Summary

This is a prospective interventional phase I/II study which will be done at Tata Medical Centre, Kolkata. Total 30 eligible female patients, ≥18 years of age, with locally advance invasive carcinoma of breast, not amenable to curative surgery of metastatic breast cancer, planned for palliative loco regional radiotherapy will be enrolled in the study amongst which patients with left sided breast cancer (at least 10) will be recruited to study the feasibility of voluntary breath hold technique for heart sparing. Once consented, all patients will have regional baseline PET-CT scan of breast and tissue biopsy along with blood sampling done before studying radiotherapy. Planning Ct scan will then be taken, with standard planning CT scan for right breast cancers with implementation voluntary breath hold technique for the left breast disease. All patients will be treated with hypo-fractionated radiotherapy with schedule of 26Gy on 5 Fractions over 1 week with 6Gy simultaneously integrated boost with incorporation of breath hold technique for left breast disease. All patients will be assessed weekly during course of radiotherapy. The toxicity will be assessed using CTCAE version 4 and LENT SOMA toxicity criteria and the impact of the hypo-fractionated breast radiotherapy schedule on quality of life in advanced incurable breast cancer patients using FACT B scores PHQ4 questionnaire will also be assessed during treatment and follow-ups tissue bio0psy will be taken after 2 hours of completion of 1 st and last fraction of radiotherapy and biobanked for future radiobiological tests. Response evaluation will be done clinically and by regional PET CT scan using PERSIST criteria in 3 months after completion of radiotherapy. After completion of treatment, patient will initially be followed up every month for 1 st three months thereby 3 monthly for 2 years and 6 monthly for next 3 years.

Conditions

Breast Cancer; Advanced Breast Cancer; Metastatic Breast Cancer

Keywords

Palliative Radiotherapy; Hypo-fractionated Radiotherapy; Simultaneous integrated boost

Outcome Measures

Primary Outcomes (1)

• Toxicity (CTCAE v 4.03)

  Proportion of patients with Grade 3 or more toxicity at 3 months evaluated as per the CTCAE v 4.03 criteria.

  3 months

Secondary Outcomes (1)

• Response

  3 months

Study Arms (1)

Hypo fractionated radiotherapy

EXPERIMENTAL

Hypo fractionated whole breast radiotherapy with simultaneous integrated boost to the tumour

Radiation: Hypo fractionated whole breast radiotherapy

Interventions

Hypo fractionated whole breast radiotherapy RADIATION

Hypo fractionated radiotherapy to the whole breast and SCF to a dose of 26 GY in 5 fractions with simultaneous integrated boost in advanced incurable breast cancer

Hypo fractionated radiotherapy

Eligibility Criteria

• Age: 18 Years+
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥18 years
• Female
• Invasive carcinoma of the breast
• ECOG performance status 0-2
• Locally advanced breast cancer which is not amenable to curative surgery as decided by multidisciplinary tumour board.
• Metastatic breast cancer patients:
• Who are awaiting palliative locoregional radiotherapy for symptom (pain bleeding, ulceration, impending fungation) control.
• Who have completed a scheduled course of palliative chemotherapy and is felt to benefit from local radiation therapy
• Able to give informed consent

You may not qualify if:

• Breast reconstruction using implants
• Concurrent cyto-toxic chemotherapy
• Prior radiation to the chest wall / breast

Sponsors & Collaborators

• Tata Medical Center: lead

Study Sites (1)

Sanjoy Chatterjee

Kolkata, West Bengal, 700160, India

Location

MeSH Terms

Conditions

Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 2, 2018
• First Posted: September 13, 2018
• Study Start: January 2, 2018
• Primary Completion: December 2, 2020
• Study Completion: September 6, 2021
• Last Updated: December 22, 2023

Record last verified: 2023-12

Data Sharing

• IPD Sharing: Will not share

Locations

IN (1)